Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • World View
  • Published:

Trastuzumab: dreams, desperation and hope

Nature Reviews Cancer volume 24, pages 287–288 (2024)Cite this article

Subjects

The story of trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor tyrosine kinases must be the key to many human diseases. It continued with H. Michael Shepard’s dedication to making a cancer therapy that attacks tumour cells, not normal cells, and Dennis Slamon’s drive to save the lives of people with breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sugarman, B. J. et al. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230, 943–945 (1985).

    Article  CAS  PubMed  Google Scholar 

  2. Urban, J. L., Shepard, H. M., Rothstein, J. L., Sugarman, B. J. & Schreiber, H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. PNAS 83, 5233–5237 (1986).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lewis, G. D., Aggarwal, B. B., Eessalu, T. E., Sugarman, B. J. & Shepard, H. M. Modulation of the growth of transformed cells by human tumor necrosis factor-α and interferon-γ. Cancer Res. 47, 5382–5385 (1987).

    CAS  PubMed  Google Scholar 

  4. Sugarman, B. J., Lewis, G. D., Eessalu, T. E., Aggarwal, B. B. & Shepard, H. M. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 47, 780–786 (1987).

    CAS  PubMed  Google Scholar 

  5. Coussens, L. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132–1139 (1985).

    Article  CAS  PubMed  Google Scholar 

  6. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).

    Article  CAS  PubMed  Google Scholar 

  7. Hudziak, R. M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165–1172 (1989).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Fendly, B. M. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550–1558 (1990).

    CAS  PubMed  Google Scholar 

  9. Pegram, M. et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241–2251 (1999).

    Article  CAS  PubMed  Google Scholar 

  10. Stohrer, M., Boucher, Y., Stangassinger, M. & Jain, R. K. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251–4255 (2000).

    CAS  PubMed  Google Scholar 

  11. Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS 89, 4285–4289 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Baselga, J. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61, 14–21 (2001).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

I wish to acknowledge Bryan Finkle who always had the utmost confidence that our work would succeed.

Author information

Authors and Affiliations

  1. Enosi Therapeutics, Knight Campus Innovation Center, Eugene, OR, USA

    H. Michael Shepard

Authors
  1. H. Michael Shepard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Michael Shepard.

Ethics declarations

Competing interests

H.M.S is an employee of Enosi Therapeutics, Inc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shepard, H.M. Trastuzumab: dreams, desperation and hope. Nat Rev Cancer 24, 287–288 (2024). https://doi.org/10.1038/s41568-024-00676-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41568-024-00676-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing